Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th
NEW YORK, Nov. 07, 2022 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., chief executive officer, will participate in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Day, taking place November 14th-15th, 2022.
| Guggenheim 4th Annual Immunology and Neurology Day fireside chat details: | |
| Date: | Monday, November 14th, 2022 |
| Time: | 3:55 pm Eastern Time |
| Webcast: | The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company’s website, located at www.immunovant.com. |
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage biopharmaceutical company dedicated to enabling normal lives for people with autoimmune diseases. As a leader in FcRn inhibitor technology, the Company is boldly developing innovative therapies for a range of debilitating autoimmune diseases with significant unmet patient needs. For additional information on the Company, please visit www.immunovant.com.
Contact:
Chau Cheng, PhD, MBA
Vice President, Investor Relations
Immunovant, Inc.
info@immunovant.com
